Brought to you by 
Amneal and Impax Labs merge to create leading generics company
10 Aug 2018
Executive Summary
Amneal Pharmaceuticals LLC and Impax Laboratories Inc. entered into a merger agreement in which the two companies will combine in an all stock transaction valued at approximately $6.2bn in market value (assumes per share price of $19.95) or $8.7bn in enterprise value (including net debt of $2.5bn; 4.8x and 13.9x EV to 2017 combined pro forma revenue and EBITDA, respectively).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Macromolecule
- Topical Delivery
- Transdermal
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amneal and Impax Labs merge to create leading generics company
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice